Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.
about
Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewInflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort studyIP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection.Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver diseaseImmune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infectionSerum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.Plasma Levels of Matrix Metalloproteinase (MMP)-2, MMP-9 and Tumor Necrosis Factor-α in Chronic Hepatitis C Virus Patients.Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C.IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.Transforming growth factor-β genetic polymorphisms on development of liver cirrhosis in a meta-analysis.Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk.Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented ReviewDetermination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail
P2860
Q24614787-26EDDFFD-1E04-4CFF-B9CB-86E5EF6720EFQ28484274-4BB3E877-154B-4D2E-995B-83B236A1DFB9Q34425282-B0475BA9-1D30-42D7-885A-4AB55ED471E2Q34630224-629C84B8-F135-4622-A16B-A9A09A8C18E0Q34673075-280978B1-D97D-4E9C-A8BB-0C3C2DD79966Q34976988-CDAEC326-85DE-41C7-8574-988599EA5557Q36227804-BFFAD7D4-6615-4472-9203-67F7A2BCE499Q40434679-C3B94177-56E3-4E02-BA76-E44AF3EDB72EQ40666389-BE8BF345-8472-4B42-B489-A95E825304F7Q40808386-1201688E-866B-4D83-A18C-F72C60252409Q40919115-FE29AAF4-7EF7-4955-929C-412D47361B23Q42232930-F93E2A15-5EEA-4AF9-8FCC-1A64A31D8B36Q46879820-1CDD9BC6-416F-4B6C-BA7B-9B5FF7CAF651Q50724625-F3048611-F1D6-410B-B8DA-B5F8BF68C6FBQ57066901-230ED0C9-8C4E-411A-A6B6-664417CF721CQ58815620-778FDD33-F2F1-4126-AD18-786E69EAD78C
P2860
Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@en
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@nl
type
label
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@en
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@nl
prefLabel
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@en
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@nl
P2093
P2860
P1476
Twelve potential fibrosis mark ...... hronic hepatitis C genotype 1.
@en
P2093
B Moessner
E S Andersen
J Eugen-Olsen
P B Christensen
P2860
P2888
P304
P356
10.1007/S10096-010-1149-Y
P577
2011-01-13T00:00:00Z
P5875
P6179
1050376072